Ideally in my world I would like to see Leronlimab work in
Ideally in my world I would like to see Leronlimab work in combination with the vaccinations. We know that the vaccines currently now are effective in over 99.99% of the time by keeping you out of the hospital. It seems the people that are having this break through infection are experiencing mild symptoms from ordinary cold symptoms to more dire flu symptoms combined with a bad cold.
My thoughts are what if… we don’t ever get rid of covid because there is this population that just won’t allow us all to get vaccinated. So as an investor this is somewhat good. For me being vaccinated keeps death off the table. I am happy about that. But now I have this bad covid cold/flu to contend with and the cytokine storm is almost off the table but is it really because this cold is just the beginning of the cytokine storm. The moderate trial in Brazil will hopefully show how we can keep a very high percentage of people from hospital care. Vaccinated or not. That’s the hope.
What if… a vaccination every 6 months was common and Leronlimab was used just for the Covid cold/flu symptoms to reduce the impact or the length of time it was a problem for the vaccinated. This could be very good for the investors if we were used for what is going to be covid forever and ever because for whatever reason we will not see the complete population or 90% of the population get vaccinated. I am starting to like the far right political wing more and more with these needs they most likely will have for Leronlimab.
Would this be a problem for us? The one drug that helps the Covid cold/flu vaccinated or not and for those unvaccinated from dying in the hospital critical patients. Then those critical patients also need us for the long haulers that up to 30% will get.
All I know is if Leronlimab works like I have hoped and just described. The size of my yacht has just increased to the size that has a pool on the aft deck. If you add in Cancer and Nash and we are adding even more size and crew size and a helicopter pad on the top deck. This is the size that I don’t have to waste all that time driving it around the Gulf of Mexico which will be my winter snow bird location. I will now have a my own yacht captain to drive me around. I am kind of liking this possibility. As break through vaccinated patients become more common we will have to start another trial for them and that pesky cold/flu symptoms. I always thought we would end up as an over the counter drug for something. This is where dose justification will be enlightening and for the mild cold/flu we would probably have a real small 350ml or smaller dose for our subcutaneous shot.
This is my first day dream I have been willing to share for some time…oh how sweet it could be!
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....
Continue Reading
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Development in Mental Health Treatment In a groundbreaking collaboration, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has joined forces with the University of North Carolina at Chapel Hill (UNC) thanks to a substantial grant from the U.S. Department of Defense. This grant aims to explore the effectiveness and safety of BXCL501, a novel treatment for acute stress...
Continue Reading
Alumni Champions of Environmental Research In a remarkable tale of collaboration fueled by a shared passion for wildlife research, Eastern Michigan University alumni Dorothy Zahor and Kenneth Glynn came together to explore environmental issues through the lens of urban wildlife. Their dedication to the study of American robins has revealed fascinating insights into how...
Continue Reading
Verkada Strengthens Global Channel Operations Verkada, known for its innovative cloud-based physical security solutions, recently announced a strategic enhancement in its global channel operations with the appointment of Micah Deriso as Head of Global Channel. This strategic move aims to bolster Verkada's global partnerships and streamline its channel strategy. Meet Micah...
Continue Reading
Purcell & Lefkowitz LLP Investigates Citi Trends, Inc. Recently, Purcell & Lefkowitz LLP announced an investigation concerning Citi Trends, Inc. (NASDAQ: CTRN). This inquiry arises from concerns regarding the fiduciary duties of the directors amidst ongoing corporate actions. The aim is to determine if there have been any breaches that may affect shareholders....
Continue Reading
Prairie Operating Co. Announces Successful Shelduck South Pad Completion Prairie Operating Co. (Nasdaq: PROP) has recently achieved a remarkable milestone with the timely completion of its Shelduck South pad in the DJ Basin. This accomplishment marks the successful culmination of the first phase of its development program for 2025, aiming for all production to be fully...
Continue Reading